Interim report January–March 2022: Building on our strong growth momentum

Cision Publicerad: 22 Apr 2022 08:00

First quarter

Sales of SEK 752 (379) million, corresponding to an increase of 98% in SEK whereof currency effect 13%, acquired growth 74% and organic growth 11%.
Consumables increased sales by 26% in SEK, Technologies by 4% in SEK, and Genetic Services contributed with sales of SEK 304 million.
Strong growth in all market regions: Americas 255%, EMEA 85%, Japan Pacific 21% and Asia 19% in local currencies.
Operating income before depreciation and amortisation (EBITDA) was SEK 228 (163) million, corresponding to a margin of 30.4% (43.0). EBITDA per share increased 13%.
Net income was SEK 82 (119) million, resulting in earnings per share of SEK 0.60 (1.09).

Pro forma
Sales, adjusted for discontinuing Covid business, increased by 18% in SEK, and 11% in local currencies.
EBITDA margin of 30.4% (34.4%).

Gothenburg, April 22, 2022
VITROLIFE AB (publ)
Thomas Axelsson, CEO